Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TGF-beta 1/Anti-COX-2 siRNAs STP707

A polypeptide nanoparticle (PNP)-based therapeutic comprised of two small interfering RNA (siRNA) oligonucleotides directed against transforming growth factor-beta 1 (TGF-beta 1) and cyclo-oxygenase-2 (COX-2), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-TGF-beta 1/anti-COX-2 siRNAs STP707 binds to both TGF-beta 1 and COX-2 messenger RNAs (mRNAs), preventing the translation and expression of TGF-beta 1 and COX-2 proteins. This inhibits TGF-beta 1-mediated signaling and abrogates TGF-beta 1-mediated immunosuppression, which may enhance anti-tumor immunity in the tumor microenvironment (TME) and promote a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. The inhibition of COX-2 prevents COX-2-mediated signaling, which may result in apoptosis and a reduction in tumor cell proliferation, tumor angiogenesis and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TGF-beta 1/anti-COX-2 siRNA oligonucleotides STP707
anti-TGF-beta 1/COX-2 siRNAs STP707
Code name:STP 707
STP-707
STP707
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search